^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Belrapzo (bendamustine RTD) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/14/2021
Excerpt:
BELRAPZO is an alkylating drug indicated for treatment of patients with…Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
